Abstract. Breast cancer patients with four or more lymph node metastases generally show poor prognosis. However, some can survive for a long period. In this study, we retrospectively evaluated these cases for estrogen receptor status and cell proliferation potential in an attempt to predict patient outcome more accurately. Ninety-two radically operated primary breast cancer patients with four or more lymph node metastases were examined. High PCNA LI and ER-negative status were significantly associated with poor outcome. Then, survival analysis was performed on combination of ER and PCNA LI status, remarkable difference was shown in the prognosis of the patients.
Introduction
Many clinicopathological factors have been proposed as markers to predict the outcome of patients with breast cancer. Among these markers, numerous studies have indicated that the number of metastatic lymph nodes is the most reliable independent marker for prediction of outcome (1) . Generally, breast cancer patients with metastatic involvement in four or more lymph nodes have a poor prognosis (2,3). Fisher et al (4) reported that the hazard ratio for breast cancer patients with no or 1 to 3 positive nodes was relatively low and constant in those with greater than or equal to 4 positive nodes. According to records of our institutes from 1980 to 1998, the 10-year survival rate after radical surgery was about 70% for all patients with breast cancer and was almost 90% for patients without lymph node metastasis. On the other hand, less than 30% of patients with four or more lymph node metastases survived 10 years after operation. Usually, extensive lymph node metastases indicate that disease has already become systemic. Most of these patients come to have distant metastases and die even after radical surgery. However, the outcome of patients with this condition varies, and approximately 30% can survive for a long period of time without disease recurrence after radical surgery. It is very difficult to predict the outcome of these patients with extensive lymph node metastasis from clinicopathological features alone.
Estrogen receptor (ER) status is also a useful prognostic indicator for breast cancer (5, 6) . Moreover, about 60% of ERpositive cancers respond well to anti-estrogen therapy (7) . ER status also appears to be closely correlated with cancer proliferation. ER acts as a ligand-inducible transcription factor and regulates many genes related to cell proliferation. ER status is thus one of the most reliable biological markers of the outcome of breast cancer patients after treatment.
Moreover, recent advances in molecular biological approaches have revealed several useful factors for prediction of the prognosis in breast cancer. Among these molecular biological markers, mutation of p53 is particularly useful. P53 status is also known to predict the efficacy of adjuvant chemotherapy that is often performed in advanced cases (8, 9) . However, frequency of p53 mutation increases with cancer progression and many tumors have already lost normal p53 gene function in advanced cases. Thus, it might be difficult to determine the prognosis of advanced cases from p53 status alone. Furthermore, the reliability of determination of p53 status largely depends on the method used. Although immunohistochemical staining is one of the easiest and most useful methods for estimation of functional abnormality of p53, falsenegative cases are always included, while mutation analysis is time-consuming and costly.
Proliferating cell nuclear antigen (PCNA) is a nuclear protein that acts as a cofactor for DNA polymerase ‰. It increases during G1 phase and is maximal in S phase (10) (11) (12) . An increasing population of PCNA-positive cells indicates strong proliferative activity. A number of studies of the effect of PCNA LI have been reported (13) (14) (15) (16) . We have reported that measurement of cellular proliferative potential, in addition to p53 status, might help to determine the prognosis of advanced breast cancer patients (17) by indicating the functional status of the p53 gene.
In this study, we investigated further in combination of clinical features of the tumors including ER status and functional p53 status for distinguishing the 'real' poor prognostic group in breast cancer patients with extensive lymph node metastasis.
Materials and methods
This study involved 92 primary breast cancer patients with four or more lymph node metastasies who underwent surgery at the Department of Surgical Oncology, Osaka City University Hospital or Department of Surgery, Osaka City General Hospital between 1980 and 1996. Patients with distant metastasis at the time of surgery were not enrolled in this study. All patients were women with a median age of 52 years (range, 22-88). The median follow-up period of the patients was 57 months (range, 6-183). Surveillance of the patients was performed by blood examinations, chest X-ray, ultrasonography and scintigraphy every 6 months. Outcome and clinicopathological parameters were investigated based on their medical records. Some patients who did not attend the hospital for a long period, the outcome was checked by telephone interview. Forty-four patients (48%) died of the disease and 15 patients (16%) survived with disease recurrence. Only one patient did not undergo adjuvant therapy, and 7 patients received hormonal therapy only. Eighty-four patients underwent chemo-endocrine combined therapy including anthracyclines and tamoxifen. There was no significant difference in survival between the regimens of the adjuvant therapies.
Estrogen receptor assay. Estrogen receptor concentration was measured by dextran-coated charcoal assay using a part of fresh surgical specimen (Otsuka Assay, Tokyo, Japan). The limit of detection was 5 fmol/mg protein and the cut-off value was determined to be 13 fmol/mg protein.
Immunohistochemical staining. Six-µm-thick sections of primary breast lesions were prepared from formalin-fixed, paraffin-embedded archival specimens which had been used for routine pathological examination. The primary antibodies were mouse monoclonal antibody DO-7 (Dako A/S, Glostrup, Denmark) for p53 and mouse monoclonal antibody PC10 (Dako A/S) for PCNA. Immunohistochemical staining was performed using the streptoavidin-biotin method. Details of the method have been described previously (17) . Each primary antibody was applied at a dilution of 1:50 for anti-p53 antibody and 1:100 for anti-PCNA antibody, then incubated overnight at 4˚C. The sections were investigated by two examiners independently without information on patients backgrounds. We interpreted the sections for p53 under light microscopy in which more than 5% of nuclei demonstrated peroxidase as being positive (18, 19) . PCNA immunostaining was scored by percentage of positive nuclei, counting at least 1000 tumor Table I . Survival data for each clinicopathological factor. 
Survival and disease-free periods were analysed by Kaplan-Meier method.
- (20) . The patients were divided into two groups by mean value of PCNA LI: PCNA LI of 21% or less (low PCNA) or more than 21% (high PCNA).
Statistics. Correlations of clinicopathological factors were analyzed by ¯2 test and differences in mean values between two groups were analyzed by Student's t-test. Survival curves for patients were calculated by the Kaplan-Meier method and analyzed by the log-rank test. The effects of each variable on survival were assessed by using a Cox proportional hazard model. A probability value less than 5% was considered statistically significant.
Results
Forty-eight cases (52%) expressed ER. P53 protein overexpression was demonstrated in 47 of 92 cases (51%). PCNA LI exhibited pronounced variation, ranging from 2.1-47.7% with a median of 21.0%. Forty-four cases (48%) were assigned to the high PCNA group.
Correlations between clinicopathological factors and prognosis are summarized in Table I . Estrogen receptor status was significantly correlated with overall survival and diseasefree survival (p=0.0005 and p=0.0007, respectively). P53 overexpression was significantly correlated with disease-free survival (p=0.0077). However, no significantly difference in overall survival was found by tumor p53 status (p=0.10). High PCNA LI was significantly associated with both shorter overall survival and shorter disease-free survival (p=0.0002 and p=0.0006, respectively). Mean PCNA LI of the patients that died (24.0±9.9%) was higher than of the patients that survived (18.1±7.4%) (p=0.0018). Mean PCNA LI of the relapsed patients (22.9±9.3%) was significantly higher than of the patients who survived without disease (17.5±7.8%) (p=0.0057).
Multivariate analysis revealed that negative ER status and high PCNA LI, but not p53 status, were independent poor prognostic factors for overall survival and disease-free survival (Table II) .
PCNA LI was closely and significantly correlated with p53 status (Fig. 1) (p=0.0004) , while no correlation was found between PCNA LI and ER status (Fig. 2) . ER-negative tumors tended to overexpress p53, although not to a significant extent. Table III shows PCNA LI according to combined ER and p53 status. PCNA LI was lowest in ER-negative and p53-positive tumors. Tumor size, existence of progesterone receptors and status of menstruation were correlated with neither p53 overexpression nor PCNA LI. ER status was not correlated with PCNA LI. ONCOLOGY REPORTS 9: 589-594, 2002 Table II. Result of multivariate analysis indicating independent useful prognostic factors. ------------------------------------------------ Table III . Correlation of p53 status and PCNA labeling index with estrogen receptor status. Combined analysis of ER and PCNA status with survival curves is demonstrated in Fig. 3 . Striking differences in overall survival and disease-free survival periods were demonstrated according to ER and PCNA status. The five-year overall survival and disease-free survival in the ER-positive and low PCNA LI group were 80 and 65%, respectively, while these in the ER-negative and high PCNA LI group were 15 and 10%, respectively. There were significant differences in overall survival and disease-free survival between these two groups (p<0.0001).
-------------------------------------------------

Discussion
Estrogen is one of the most important factors in breast cancer cells for their development and proliferation (21) (22) (23) . Estrogen functions through reaction with estrogen receptors. Although breast cancer cells exhibit ER at the time of carcinogenesis, ER-positive cells gradually decrease in number with cancer progression (24, 25) . In our series, ER was lost in 48% of cases. This was frequent compared with other studies including patients with early-stage disease (2, 3, 5) . Although ER-negative tumor was found frequently in our series, ER status of tumor was also found to be an independent prognostic factor for prediction of outcome by multivariate analysis. These observations suggested the importance of loss of ER as an indicator not only of disease progression in breast cancer, but also of the biological aggressiveness of cancer cells. Many studies have reported a correlation between loss of ER in breast cancer and early recurrence, suggesting that tumors that have lost ER are highly aggressive (5, 6) . Our results are in line with those observations and suggests that the nature of the cancer cells in the primary tumor is still important even after extensive lymph node metastasis in determining disease character.
Recently, interaction between ER and p53 is being investigating. Liu et al (26) reported that ER protects wild-type p53 from being deactivated by ligand-independent interaction of ER with the NH2-terminal of p53. Therefore, proliferative activities of ER-positive cancer cells would be restricted by p53 induced cell cycle control under protection of ER. In our investigations, ER-positive and p53-negative cancers tend to exhibited low PCNA LI, and ER-negative and p53-positive cancers tend to show high PCNA LI. These results may suggest that the effects of ER and p53 upon cell proliferation activity can be measured quantitatively with PCNA LI. Although ER regulates p53 function both directly and indirectly, it is not the sole regulatory factor but a part of numerous signal transmission pathways to p53 (26) (27) (28) . On the other hand, p53 abnormality strongly affects signal flows in cell cycle regulation (29) (30) (31) . For these reasons, p53-positive tumor has strong cell proliferation activity in spite of ER-positive status, then PCNA LI becomes high. Moreover, cell proliferation of ER-negative and p53-positive tumor cannot be inhibited because there is no restriction factor in cell cycle regulation.
Although it might be a good way to predict the cellular proliferative potential by combination of ER and p53 status, we could not obtain clear results with statistical difference. It is known that determination of p53 status by immunohistochemistry alone is insufficient for evaluation mutation or function of p53 (32, 33) . As stated earlier, cellular proliferative potential is strictly and widely regulated by p53 gene status. We therefore used PCNA LI instead of p53 staining status. Since p53 and PCNA LI were correlated well in this study, PCNA LI may reflect p53 function quantitatively. Moreover, as shown by our results, ER status and PCNA LI were independent strong prognostic factors. Thus, it is useful to characterize tumors by combination of ER status and PCNA LI.
In this study, combination of ER status and PCNA LI can clearly separate patients' destiny. ER-positive or low PCNA scored patients have relatively good prognosis in spite of extensive lymph node metastasis. The 10-year survival rate in this group was similar to that for patients with limited lymph 
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node metastasis (not more than 3 nodes). From the perspective of relatively good prognosis rather than nodal status, patients in this group might be receiving proper adjuvant chemo-endocrine therapy. On the other hand, we must consider the strategy of treatment for the high PCNA and ER-negative group. The survival curves in this group fall rapidly, and are similar to or worse than that for patient with distant metastasis. From these observations, chemo-, radiation and/or endocrine therapies may not be of sufficient efficacy for this group of patients by conventional way. Because the efficacy of these conventional therapies largely depend upon ER and p53 status. Newly developed molecular biological treatments, for example p53 or p21 gene induction therapy (34, 35) or anti-HER-2/neu antibody (36) may be more appropriate. These therapies are conducted either recovery of the cellular regulatory mechanism against insufficient proliferation and apoptosis or intervention upon an absolutely different target that was not employed in p53 dependent pathway. Moreover, recent studies have suggested the independence of ER status and HER-2/neu status (37, 38) . Our results suggested that combined analysis of ER and PCNA status can predict the outcome of advanced breast cancer and can be used to establish a strategy for treatment. It would be very interesting if our observations could be supported in a prospective setting.
